Unknown

Dataset Information

0

Impact of a new levonorgestrel intrauterine system, Levosert(®), on heavy menstrual bleeding: results of a one-year randomised controlled trial.


ABSTRACT: OBJECTIVE: To evaluate a new levonorgestrel-releasing intrauterine system (LNG-IUS) called Levosert(®) for the treatment of heavy menstrual bleeding (HMB) in comparison to the reference product Mirena(®). METHODS: A multicentre, randomised, controlled trial, in non-menopausal women diagnosed with functional HMB (defined as menstrual blood loss [MBL] ? 80 mL) randomised to either Levosert(®) or Mirena(®) and followed for up to one year. MBL was evaluated using a validated modified version of the Wyatt pictogram. RESULTS: A total of 280 women were randomised (141 to Levosert(®) and 139 to Mirena(®)). During the one-year treatment period, both Levosert(®) and Mirena(®) dramatically decreased MBL and increased haemoglobin and ferritin levels. There were no statistically significant differences between Levosert(®) and Mirena(®) regarding any of the parameters evaluated during the study. Similar bleeding patterns were observed in both groups. Levosert(®) was inserted with the same ease as Mirena(®). Both treatments were associated with identical expulsion rates and no perforations occurred in either treatment group. CONCLUSION: Levosert(®), a new LNG-IUS designed to release the same daily amount of LNG as Mirena(®), is highly effective in the treatment of HMB. No differences were observed between Levosert(®) and Mirena(®) regarding all evaluated outcomes, including safety profile.

SUBMITTER: Mawet M 

PROVIDER: S-EPMC4133966 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of a new levonorgestrel intrauterine system, Levosert(®), on heavy menstrual bleeding: results of a one-year randomised controlled trial.

Mawet Marie M   Nollevaux Fabrice F   Nizet Dominique D   Wijzen Fabienne F   Gordenne Valérie V   Tasev Niso N   Segedi Dimitrije D   Marinescu Bogdan B   Enache Andreea A   Parhomenko Vadim V   Frankenne Francis F   Foidart Jean-Michel JM  

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 20140326 3


<h4>Objective</h4>To evaluate a new levonorgestrel-releasing intrauterine system (LNG-IUS) called Levosert(®) for the treatment of heavy menstrual bleeding (HMB) in comparison to the reference product Mirena(®).<h4>Methods</h4>A multicentre, randomised, controlled trial, in non-menopausal women diagnosed with functional HMB (defined as menstrual blood loss [MBL] ≥ 80 mL) randomised to either Levosert(®) or Mirena(®) and followed for up to one year. MBL was evaluated using a validated modified ve  ...[more]

Similar Datasets

| S-EPMC10108838 | biostudies-literature
| S-EPMC10209678 | biostudies-literature
| S-EPMC5159479 | biostudies-literature
| S-EPMC8518490 | biostudies-literature
| S-EPMC9309137 | biostudies-literature
| S-EPMC9235075 | biostudies-literature
| S-EPMC4366870 | biostudies-literature
| S-EPMC2922496 | biostudies-literature
| S-EPMC4017944 | biostudies-literature
| S-EPMC9413853 | biostudies-literature